Later, Cusi and colleagues demonstrated in clinical trials of the PPARγ activator pioglitazone that adiponectin elevation is the best predictor of histologic response in NASH and fibrosis (256, 257). Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.